查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1859214

肺癌诊断市场报告：趋势、预测和竞争分析（至2031年）

Lung Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球肺癌诊断市场前景广阔，在工业和医疗保健领域均蕴藏着巨大机会。预计2025年至2031年，全球肺癌诊断市场将以5.7%的复合年增长率成长。推动该市场发展的关键因素包括全球肺癌发病率的上升、非侵入性液态切片的日益普及以及人工智慧成像技术的广泛应用。

  • Lucintel 预测，在预测期内，分子检测将成为成长最快的检测类型。
  • 从应用领域来看，医疗保健产业预计将呈现高速成长。
  • 从区域来看，预计亚太地区在预测期内将达到最高成长。

肺癌诊断市场的新趋势

在基因组学、影像学和人工智慧等技术的进步推动下，肺癌诊断市场目前正经历着重大变革。这些新兴趋势将显着提高肺癌诊断的准确性、可近性和个人化程度，最终改善患者的治疗效果。

  • 液态切片的应用：液态切片透过分析血液中的循环肿瘤DNA（ctDNA）和其他生物标记物，正迅速成为新兴趋势。这种非侵入性方法为组织切片检查提供了一种创伤更小的替代方案，能够实现更早期的肿瘤检测、治疗反应监测和抗药性机制识别，从而彻底改变患者管理。
  • 人工智慧和机器学习在诊断成像中的应用：将人工智慧 (AI) 和机器学习 (ML) 整合到诊断成像（电脑断层扫描、X 光片）中是一种强劲的发展趋势。 AI 演算法能够增强对细微结节的检测，减少假阳性结果，提高诊断准确率，并帮助放射科医生高效分析大量影像数据，从而实现更早、更准确的诊断。
  • 多组体学分析：目前，结合基因组学、蛋白质组学和代谢组学数据进行肺癌全面诊断的多体学分析正成为日益流行的趋势。这种整合方法能够辨识复杂的分子特征，更精确地对患者进行分层，并指导高度个人化的治疗策略，从而获得更佳的治疗效果。
  • 照护现场诊断：快速、便携、易用的即时诊断（POC）设备的开发正成为一种新兴趋势，尤其是在生物标记检测领域。这些设备能够在非专业环境下进行快速筛检和初步诊断，从而提高偏远和资源匮乏地区的诊断可及性。
  • 远端医疗整合：肺癌诊断与远端医疗平台的整合是一种加速发展的趋势，它能够进行远距会诊、诊断影像解读和后续随访，从而改善获得专家意见的机会，并减少就医的地域障碍，这对服务不足的人群尤其重要。

这些趋势正在显着地重塑肺癌诊断市场，使其朝向侵入性更小、更准确、高度个人化的诊断方法发展，同时提高可及性和效率，最终提高早期发现率，并带来更有效、更有针对性的治疗策略。

肺癌诊断市场近期趋势

近年来，肺癌诊断市场经历了几个关键性的发展趋势，这主要得益于全球对早期检测的重视、分子生物学的进步以及数位技术的融合应用。这些变革旨在提高诊断准确度、降低侵入性并改善患者预后。

  • 低剂量 CT筛检的兴起：一项关键进展是全球范围内采用和接受低剂量电脑断层扫描 (LDCT) 作为高危险群肺癌筛检的标准，与传统方法相比，可更早发现更小、更易治疗的肿瘤，并显着提高生存率。
  • 液态切片的进展：近期发展凸显了液态切片的快速进步和日益增长的临床效用。这项非侵入性技术能够从血液样本中检测循环肿瘤DNA（ctDNA）、循环性肿瘤细胞（CTC）和其他生物标记物，从而实现早期诊断、个人化治疗选择和復发监测。
  • 人工智慧在放射学中的应用：近年来，人工智慧（AI）和机器学习演算法在诊断放射成像领域的应用日益广泛。人工智慧工具能够帮助放射科医师更准确、有效率地识别和表征可疑的肺结节，从而减少假阳性结果并改善诊断流程。
  • 扩展的分子谱分析：肺癌的综合分子谱分析取得了显着进展，从单基因突变扩展到多基因panel和次世代定序（NGS），这提供了更详细的肿瘤基因图谱，对于指南精准肿瘤学中的标靶治疗和免疫治疗至关重要。
  • 新型生物标记开发：近期趋势包括发现和检验新型诊断和预后生物标记，包括特定蛋白质、微型RNA和表观遗传标记物，透过各种平台检测这些标记有助于早期诊断、预测治疗反应和监测疾病进展，从而增强个人化治疗。

这些治疗方法正在显着影响肺癌诊断市场，推动人们转向更积极的筛检、更少侵入性的诊断方法以及基于详细分子资讯的高度个人化的治疗方法，最终改善患者的护理和生存率。

目录

第一章执行摘要

第二章 市场概览

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章 全球肺癌诊断市场（按类型划分）

  • 概述
  • 吸引力分析：按类型
  • 免疫测定：趋势与预测（2019-2031）
  • 流式细胞技术：趋势与预测（2019-2031）
  • 快速检测：趋势与预测（2019-2031）
  • 分子检测：趋势与预测（2019-2031）
  • 组织晶片：趋势与预测（2019-2031）
  • 循环性肿瘤细胞：趋势与预测（2019-2031）
  • 药物诊断：趋势与预测（2019-2031）
  • 生物标记：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031 年）

第五章 全球肺癌诊断市场（依应用划分）

  • 概述
  • 吸引力分析：依目的
  • 产业：趋势与预测（2019-2031）
  • 医疗保健：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031 年）

第六章 区域分析

  • 概述
  • 全球肺癌诊断市场（按地区划分）

7. 北美肺癌诊断市场

  • 概述
  • 北美肺癌诊断市场按类型划分
  • 北美肺癌诊断市场按应用领域划分
  • 美国肺癌诊断市场
  • 墨西哥肺癌诊断市场
  • 加拿大肺癌诊断市场

8. 欧洲肺癌诊断市场

  • 概述
  • 欧洲肺癌诊断市场按类型划分
  • 欧洲肺癌诊断市场按应用领域划分
  • 德国肺癌诊断市场
  • 法国肺癌诊断市场
  • 西班牙肺癌诊断市场
  • 义大利肺癌诊断市场
  • 英国肺癌诊断市场

9. 亚太地区肺癌诊断市场

  • 概述
  • 亚太地区肺癌诊断市场（按类型划分）
  • 亚太地区肺癌诊断市场按应用划分
  • 日本肺癌诊断市场
  • 印度肺癌诊断市场
  • 中国肺癌诊断市场
  • 韩国肺癌诊断市场
  • 印尼肺癌诊断市场

第十章 世界其他地区（ROW）肺癌诊断市场

  • 概述
  • ROW肺癌诊断市场按类型划分
  • ROW肺癌诊断市场按应用领域划分
  • 中东肺癌诊断市场
  • 南美洲肺癌诊断市场
  • 非洲肺癌诊断市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 透过申请获得发展机会
  • 全球肺癌诊断市场新兴趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 企业合併、协议、合作关係和合资企业

第十三章：价值链中主要企业的概况

  • 竞争分析
  • Roche Diagnostics
  • BioMerieux
  • Qiagen
  • Advpharma
  • AIT Austrian Institute of Technology
  • Courtagen Life Sciences
  • DiagnoCure
  • BioMark Diagnostics
  • Mayo Clinic
  • HalioDx SAS

第十四章附录

  • 图表清单
  • 表格列表
  • 分析方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于 Lucintel
  • 询问

The future of the global lung cancer diagnostic market looks promising with opportunities in the industrial and healthcare markets. The global lung cancer diagnostic market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the increasing global lung cancer incidence rates, the rising adoption of non-invasive liquid biopsies, and the growing implementation of ai-driven imaging technologies.

  • Lucintel forecasts that, within the type category, molecular assay is expected to witness the highest growth over the forecast period.
  • Within the application category, healthcare is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is currently at the cusp of a major transformation, fueled by advancements in genomics, imaging, and artificial intelligence. These emerging trends are significantly improving the accuracy, accessibility, and personalization of lung cancer diagnosis, ultimately leading to better patient outcomes.

  • Liquid Biopsy Adoption: Liquid biopsy, which involves analyzing blood for circulating tumor DNA (ctDNA) or other biomarkers, is a rapidly emerging trend. This non-invasive method offers a less burdensome alternative to tissue biopsies, enabling earlier detection, monitoring treatment response, and identifying resistance mechanisms, thus revolutionizing patient management.
  • AI and Machine Learning in Imaging: The integration of Artificial Intelligence (AI) and Machine Learning (ML) into diagnostic imaging (CT scans, X-rays) is a powerful trend. AI algorithms enhance the detection of subtle nodules, reduce false positives, and improve diagnostic accuracy, assisting radiologists in efficiently analyzing large volumes of imaging data for early and precise diagnosis.
  • Multi-Omics Profiling: There's an increasing trend towards multi-omics profiling, combining genomic, proteomic, and metabolomic data for comprehensive lung cancer diagnosis. This holistic approach identifies complex molecular signatures, leading to more precise stratification of patients and guiding highly individualized therapeutic strategies for superior outcomes.
  • Point-of-Care Diagnostics: The development of rapid, portable, and easy-to-use Point-of-Care (POC) diagnostic devices is an emerging trend, especially for biomarker detection. These devices enable quick screening and initial diagnosis in non-specialized settings, improving accessibility to diagnostics in remote or resource-limited areas.
  • Integration with Telemedicine: The integration of lung cancer diagnostics with telemedicine platforms is an accelerating trend. This allows for remote consultation, interpretation of diagnostic images, and follow-up, improving access to specialist opinions and reducing geographical barriers to care, particularly vital for underserved populations.

These trends are profoundly reshaping the lung cancer diagnostic market by shifting towards less invasive, more accurate, and highly personalized diagnostic approaches. They are also improving accessibility and efficiency, ultimately enhancing early detection rates and guiding more effective, targeted treatment strategies.

Recent Developments in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market has witnessed several pivotal recent developments, primarily driven by a global push for early detection, advancements in molecular biology, and the integration of digital technologies. These changes aim to enhance diagnostic accuracy, reduce invasiveness, and improve patient outcomes.

  • Rise of Low-Dose CT Screening: A significant development is the increasing global adoption and endorsement of Low-Dose Computed Tomography (LDCT) as the standard for lung cancer screening in high-risk individuals. This has led to earlier detection of smaller, more treatable tumors, significantly improving survival rates compared to traditional methods.
  • Advancements in Liquid Biopsy: Recent developments highlight the rapid progress and increasing clinical utility of liquid biopsy. This non-invasive technology allows for the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from blood samples, enabling early diagnosis, personalized treatment selection, and monitoring for recurrence.
  • Integration of AI in Radiology: A key recent development is the growing integration of Artificial Intelligence (AI) and machine learning algorithms into radiological imaging. AI-powered tools assist radiologists in identifying and characterizing suspicious lung nodules more accurately and efficiently, reducing false positives and improving diagnostic workflows.
  • Expanded Molecular Profiling: There's a notable development in the comprehensive molecular profiling of lung cancer, moving beyond single gene mutations to include multi-gene panels and next-generation sequencing (NGS). This provides a more detailed genetic blueprint of the tumor, crucial for guiding targeted therapies and immunotherapies in precision oncology.
  • Development of Novel Biomarkers: Recent developments include the discovery and validation of new diagnostic and prognostic biomarkers. These include specific proteins, microRNAs, and epigenetic markers, which can be detected through various platforms to aid in early diagnosis, predict treatment response, and monitor disease progression, enhancing personalized care.

These developments are profoundly impacting the lung cancer diagnostic market by fostering a shift towards more proactive screening, less invasive diagnostic methods, and highly personalized treatment approaches based on detailed molecular information, ultimately improving patient care and survival rates.

Strategic Growth Opportunities in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market offers substantial strategic growth opportunities across various key application areas, driven by the increasing global burden of lung cancer, continuous technological innovations, and a rising emphasis on early detection and personalized medicine. Identifying and capitalizing on these segments is crucial for market players to achieve sustainable growth.

  • Early Lung Cancer Screening Programs: The expansion of population-based lung cancer screening programs using LDCT, particularly for high-risk individuals (e.g., heavy smokers), presents a significant growth opportunity. This drives demand for imaging equipment, AI-powered diagnostic software, and associated pathology services for nodule work-up.
  • Personalized Medicine and Biomarker Testing: The accelerating shift towards personalized medicine in oncology creates a robust growth avenue. The demand for comprehensive biomarker testing (e.g., EGFR, ALK, PD-L1, KRAS) using molecular diagnostics (NGS, PCR) and liquid biopsies is paramount for guiding targeted therapies and immunotherapies.
  • Post-Treatment Monitoring and Recurrence Detection: Providing diagnostic solutions for monitoring patients post-treatment and detecting early recurrence offers a strategic growth opportunity. Liquid biopsies, with their non-invasive nature, are increasingly valuable for serial monitoring of minimal residual disease and identifying emergent resistance mutations, guiding subsequent treatment decisions.
  • Point-of-Care Diagnostics in Primary Care: The development and deployment of accessible point-of-care (POC) diagnostic tests, particularly for early symptom assessment or initial biomarker screening in primary care settings, presents a valuable opportunity. This can facilitate quicker referrals and reduce diagnostic delays, especially in underserved areas.
  • Research and Drug Development Partnerships: Collaborating with pharmaceutical and biotechnology companies for companion diagnostics and clinical trial support offers a high-value, strategic growth opportunity. Developing diagnostic assays that identify patients most likely to respond to novel targeted therapies or immunotherapies is critical for drug development and regulatory approval.

These opportunities are profoundly impacting the lung cancer diagnostic market by shifting focus towards proactive screening, precision-based treatment guidance, continuous monitoring, and accessible diagnostic tools, thus expanding the market's reach and value across the entire patient journey.

Lung Cancer Diagnostic Market Driver and Challenges

The lung cancer diagnostic market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. Understanding these primary drivers that propel market expansion and the significant challenges that may impede its growth is crucial for strategic decision-making by industry stakeholders.

The factors responsible for driving the lung cancer diagnostic market include:

1. Rising Incidence of Lung Cancer: The increasing global incidence of lung cancer, primarily due to factors like smoking, air pollution, and an aging population, is the most significant market driver. This escalating disease burden directly translates to a heightened demand for effective diagnostic tools and early detection strategies.

2. Growing Awareness for Early Detection: Increased public and physician awareness regarding the benefits of early lung cancer detection and the availability of screening programs (like LDCT) is a major driver. Public health campaigns and educational initiatives encourage high-risk individuals to undergo screening, boosting diagnostic volumes.

3. Technological Advancements in Diagnostics: Continuous innovations in diagnostic technologies, including high-resolution imaging, liquid biopsy, next-generation sequencing, and AI-powered analytics, are propelling market growth. These advancements lead to more accurate, less invasive, and faster diagnostic results, driving adoption.

4. Shift Towards Precision Medicine: The paradigm shift towards precision medicine in oncology significantly drives the demand for comprehensive diagnostic testing. Identifying specific genetic mutations and biomarkers is crucial for selecting targeted therapies and immunotherapies, leading to personalized and more effective treatment outcomes.

5. Favorable Reimbursement Policies: The increasing coverage and reimbursement for lung cancer screening (e.g., LDCT) and advanced molecular diagnostic tests by government and private payers are crucial market drivers. Favorable reimbursement policies enhance accessibility and affordability, encouraging broader adoption of diagnostic services.

Challenges in the lung cancer diagnostic market are:

1. High Cost of Advanced Diagnostics: The significant cost associated with advanced diagnostic technologies, such as comprehensive molecular profiling (NGS) and liquid biopsies, presents a major challenge. This can limit accessibility, particularly in developing regions or for patients without adequate insurance coverage, hindering widespread adoption.

2. Lack of Skilled Professionals: There is a global shortage of highly skilled healthcare professionals, including radiologists, pulmonologists, and molecular pathologists, trained in interpreting complex diagnostic tests and managing screening programs. This scarcity can impact the efficient implementation and scalability of advanced diagnostic services.

3. False Positives and Overdiagnosis: Lung cancer screening, particularly with LDCT, can lead to false-positive findings, necessitating additional invasive procedures and causing patient anxiety. The risk of overdiagnosis (detecting indolent tumors that would not have caused harm) also presents a challenge, requiring careful patient selection and management strategies.

The lung cancer diagnostic market is experiencing robust expansion, primarily fueled by the increasing global incidence of lung cancer, growing awareness for early detection, and rapid technological advancements, especially in precision medicine. However, significant challenges such as the high cost of advanced diagnostics, a shortage of skilled professionals, and concerns regarding false positives and overdiagnosis necessitate continuous innovation and strategic solutions to ensure equitable access and optimal patient care.

List of Lung Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies lung cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer diagnostic companies profiled in this report include-

  • Roche Diagnostics
  • BioMerieux
  • Qiagen
  • Advpharma
  • AIT Austrian Institute of Technology
  • Courtagen Life Sciences
  • DiagnoCure
  • BioMark Diagnostics
  • Mayo Clinic
  • HalioDx SAS

Lung Cancer Diagnostic Market by Segment

The study includes a forecast for the global lung cancer diagnostic market by type, application, and region.

Lung Cancer Diagnostic Market by Type [Value from 2019 to 2031]:

  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics
  • Biomarkers
  • Others

Lung Cancer Diagnostic Market by Application [Value from 2019 to 2031]:

  • Industrial
  • Healthcare
  • Others

Lung Cancer Diagnostic Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is undergoing a transformative period, driven by advancements in early detection, precision medicine, and the integration of cutting-edge technologies. Recent developments focus on improving screening efficacy, developing non-invasive diagnostic tools, and identifying specific biomarkers to enable more personalized and effective treatment strategies for patients globally.

  • United States: The U.S. market is heavily influenced by updated screening guidelines recommending low-dose CT for high-risk individuals. Recent developments include increased adoption of liquid biopsy for molecular profiling, growing interest in AI-powered image analysis to enhance diagnostic accuracy, and a strong push towards integrating these advanced diagnostics into clinical practice for personalized treatment.
  • China: China lung cancer diagnostic market is rapidly expanding, with significant government support for early screening programs. Recent developments include widespread adoption of LDCT, increasing research and application of liquid biopsy for early detection and treatment monitoring, and a growing emphasis on AI-assisted diagnostics to manage the high volume of cases and improve efficiency.
  • Germany: Germany has recently approved lung cancer screening as a benefit for statutory health insurance, signaling a major development. This will drive increased LDCT utilization. Recent developments also emphasize precision medicine, with growing use of molecular diagnostics for biomarker testing, alongside strong quality assurance requirements for screening programs, aligning with European healthcare standards.
  • India: India lung cancer diagnostic market is growing due to increasing incidence and a push for early detection. Recent developments include initiatives like "LungLife" screening programs, increased adoption of LDCT, and a focus on identifying India-specific high-risk populations for targeted screening, with ongoing research into cost-effective blood-based biomarkers.
  • Japan: Japan lung cancer diagnostic market is marked by technological sophistication and a focus on automation. Recent developments include extensive research and application of AI in analyzing CT images for nodule detection and characterization, with ultra-lightweight AI models being developed for accessible diagnostics, enhancing early detection efforts and reducing radiologist workload.

Features of the Global Lung Cancer Diagnostic Market

  • Market Size Estimates: Lung cancer diagnostic market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Lung cancer diagnostic market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Lung cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the lung cancer diagnostic market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the lung cancer diagnostic market by type (immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, biomarkers, and others), application (industrial, healthcare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Lung Cancer Diagnostic Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Immunoassays: Trends and Forecast (2019-2031)
  • 4.4 Flow Cytometry: Trends and Forecast (2019-2031)
  • 4.5 Rapid Tests: Trends and Forecast (2019-2031)
  • 4.6 Molecular Assays: Trends and Forecast (2019-2031)
  • 4.7 Tissue Arrays: Trends and Forecast (2019-2031)
  • 4.8 Circulating Tumor Cells: Trends and Forecast (2019-2031)
  • 4.9 Pharmacodiagnostics: Trends and Forecast (2019-2031)
  • 4.10 Biomarkers: Trends and Forecast (2019-2031)
  • 4.11 Others: Trends and Forecast (2019-2031)

5. Global Lung Cancer Diagnostic Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Industrial: Trends and Forecast (2019-2031)
  • 5.4 Healthcare: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Lung Cancer Diagnostic Market by Region

7. North American Lung Cancer Diagnostic Market

  • 7.1 Overview
  • 7.2 North American Lung Cancer Diagnostic Market by Type
  • 7.3 North American Lung Cancer Diagnostic Market by Application
  • 7.4 United States Lung Cancer Diagnostic Market
  • 7.5 Mexican Lung Cancer Diagnostic Market
  • 7.6 Canadian Lung Cancer Diagnostic Market

8. European Lung Cancer Diagnostic Market

  • 8.1 Overview
  • 8.2 European Lung Cancer Diagnostic Market by Type
  • 8.3 European Lung Cancer Diagnostic Market by Application
  • 8.4 German Lung Cancer Diagnostic Market
  • 8.5 French Lung Cancer Diagnostic Market
  • 8.6 Spanish Lung Cancer Diagnostic Market
  • 8.7 Italian Lung Cancer Diagnostic Market
  • 8.8 United Kingdom Lung Cancer Diagnostic Market

9. APAC Lung Cancer Diagnostic Market

  • 9.1 Overview
  • 9.2 APAC Lung Cancer Diagnostic Market by Type
  • 9.3 APAC Lung Cancer Diagnostic Market by Application
  • 9.4 Japanese Lung Cancer Diagnostic Market
  • 9.5 Indian Lung Cancer Diagnostic Market
  • 9.6 Chinese Lung Cancer Diagnostic Market
  • 9.7 South Korean Lung Cancer Diagnostic Market
  • 9.8 Indonesian Lung Cancer Diagnostic Market

10. ROW Lung Cancer Diagnostic Market

  • 10.1 Overview
  • 10.2 ROW Lung Cancer Diagnostic Market by Type
  • 10.3 ROW Lung Cancer Diagnostic Market by Application
  • 10.4 Middle Eastern Lung Cancer Diagnostic Market
  • 10.5 South American Lung Cancer Diagnostic Market
  • 10.6 African Lung Cancer Diagnostic Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Lung Cancer Diagnostic Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Roche Diagnostics
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 BioMerieux
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Qiagen
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Advpharma
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 AIT Austrian Institute of Technology
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Courtagen Life Sciences
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 DiagnoCure
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 BioMark Diagnostics
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Mayo Clinic
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 HalioDx SAS
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Lung Cancer Diagnostic Market
  • Figure 2.1: Usage of Lung Cancer Diagnostic Market
  • Figure 2.2: Classification of the Global Lung Cancer Diagnostic Market
  • Figure 2.3: Supply Chain of the Global Lung Cancer Diagnostic Market
  • Figure 3.1: Driver and Challenges of the Lung Cancer Diagnostic Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Lung Cancer Diagnostic Market ($B) by Type
  • Figure 4.3: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Immunoassays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Flow Cytometry in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Rapid Tests in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Molecular Assays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.8: Trends and Forecast for Tissue Arrays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.9: Trends and Forecast for Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.10: Trends and Forecast for Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.11: Trends and Forecast for Biomarkers in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.12: Trends and Forecast for Others in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.1: Global Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Lung Cancer Diagnostic Market ($B) by Application
  • Figure 5.3: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Industrial in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Healthcare in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 6.1: Trends of the Global Lung Cancer Diagnostic Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 7.3: Forecast for the North American Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 7.4: North American Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 7.6: Forecast for the North American Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.1: European Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 8.3: Forecast for the European Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 8.4: European Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 8.6: Forecast for the European Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.1: APAC Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 9.3: Forecast for the APAC Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 9.4: APAC Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 9.6: Forecast for the APAC Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.1: ROW Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 10.3: Forecast for the ROW Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 10.4: ROW Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 10.6: Forecast for the ROW Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Lung Cancer Diagnostic Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Lung Cancer Diagnostic Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Type
  • Figure 12.2: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Application
  • Figure 12.3: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Region
  • Figure 12.4: Emerging Trends in the Global Lung Cancer Diagnostic Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Lung Cancer Diagnostic Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Lung Cancer Diagnostic Market by Region
  • Table 1.3: Global Lung Cancer Diagnostic Market Parameters and Attributes
  • Table 3.1: Trends of the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 3.2: Forecast for the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Lung Cancer Diagnostic Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.4: Trends of Immunoassays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.5: Forecast for Immunoassays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.6: Trends of Flow Cytometry in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.7: Forecast for Flow Cytometry in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.8: Trends of Rapid Tests in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.9: Forecast for Rapid Tests in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.10: Trends of Molecular Assays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.11: Forecast for Molecular Assays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.12: Trends of Tissue Arrays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.13: Forecast for Tissue Arrays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.14: Trends of Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.15: Forecast for Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.16: Trends of Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.17: Forecast for Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.18: Trends of Biomarkers in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.19: Forecast for Biomarkers in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.20: Trends of Others in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.21: Forecast for Others in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Lung Cancer Diagnostic Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.4: Trends of Industrial in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.5: Forecast for Industrial in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.6: Trends of Healthcare in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.7: Forecast for Healthcare in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.1: Trends of the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.2: Forecast for the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Lung Cancer Diagnostic Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Lung Cancer Diagnostic Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.1: Trends of the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.2: Forecast for the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.1: Trends of the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.2: Forecast for the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.1: Trends of the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.2: Forecast for the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Lung Cancer Diagnostic Market (2019-2031)
  • Table 11.1: Product Mapping of Lung Cancer Diagnostic Suppliers Based on Segments
  • Table 11.2: Operational Integration of Lung Cancer Diagnostic Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Lung Cancer Diagnostic Revenue
  • Table 12.1: New Product Launches by Major Lung Cancer Diagnostic Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Lung Cancer Diagnostic Market